The field of pharmacophore modeling has steadily emerged as a cornerstone in the rational design of kinase inhibitors. By abstracting the essential molecular features required for optimal binding to ...

Quantum computing systems and software company D-Wave Quantum Inc. has partnered with the pharmaceutical division of Japan Tobacco Inc. to build a proof-of-concept artificial intelligence model using ...

Researchers from the Massachusetts Institute of Technology (MIT) Jameel Clinic for Machine Learning in Health have announced the open-source release of Boltz-2, which now predicts molecular binding ...

Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.

Bissan Al-Lazikani (left) is a Professor of Genomic Medicine and Director of Therapeutics Data Science at The University of Texas MD Anderson Cancer Center (Houston, TX, USA), where she heads an ...

Regina Barzilay is a School of Engineering Distinguished Professor of AI & Health in the department of computer science and the AI faculty lead at MIT Jameel Clinic. She develops machine learning ...

Genesis’ proprietary foundation model – Pearl – outperforms frontier models, including AlphaFold 3, on key benchmarks that predict utility in real-world drug discovery Pearl’s performance improved ...

Traditionally, developing a new drug takes many years and requires a massive financial investment, often involving significant risk and a high likelihood of failure. AI models trained on extensive ...

In 2025, Generative AI will prove transformational for drug discovery in the healthcare industry. With the use of deep learning and advanced algorithms, generative AI can promote acceleration in the ...